Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 275

1.

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.

Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G.

Circulation. 2004 Aug 24;110(8):904-10. Epub 2004 Aug 9.

2.

Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine.

Sicouri S, Timothy KW, Zygmunt AC, Glass A, Goodrow RJ, Belardinelli L, Antzelevitch C.

Heart Rhythm. 2007 May;4(5):638-47. Epub 2007 Jan 7.

3.

Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.

Antzelevitch C, Belardinelli L, Wu L, Fraser H, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Goodrow RJ Jr, Scornik F, Perez G.

J Cardiovasc Pharmacol Ther. 2004 Sep;9 Suppl 1:S65-83. Review.

PMID:
15378132
4.
6.

Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.

Song Y, Shryock JC, Wu L, Belardinelli L.

J Cardiovasc Pharmacol. 2004 Aug;44(2):192-9.

PMID:
15243300
7.

Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.

Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S.

Br J Pharmacol. 2004 Aug;142(8):1300-8. Epub 2004 Jul 26.

8.

Effects of ranolazine on torsades de pointes tachycardias in a healthy isolated rabbit heart model.

Sossalla S, Wallisch N, Toischer K, Sohns C, Vollmann D, Seegers J, Lüthje L, Maier LS, Zabel M.

Cardiovasc Ther. 2014 Aug;32(4):170-7. doi: 10.1111/1755-5922.12078.

9.

Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model.

Antoons G, Oros A, Beekman JD, Engelen MA, Houtman MJ, Belardinelli L, Stengl M, Vos MA.

J Am Coll Cardiol. 2010 Feb 23;55(8):801-9. doi: 10.1016/j.jacc.2009.10.033.

10.

Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.

Aiba T, Shimizu W, Inagaki M, Noda T, Miyoshi S, Ding WG, Zankov DP, Toyoda F, Matsuura H, Horie M, Sunagawa K.

J Am Coll Cardiol. 2005 Jan 18;45(2):300-7.

11.

Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing.

Fish JM, Di Diego JM, Nesterenko V, Antzelevitch C.

Circulation. 2004 May 4;109(17):2136-42. Epub 2004 Apr 12.

12.

Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current.

Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN.

J Cardiovasc Electrophysiol. 2006 May;17 Suppl 1:S169-S177.

13.

Cellular basis for complex T waves and arrhythmic activity following combined I(Kr) and I(Ks) block.

Emori T, Antzelevitch C.

J Cardiovasc Electrophysiol. 2001 Dec;12(12):1369-78.

PMID:
11797994
15.

Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart.

Wu L, Rajamani S, Li H, January CT, Shryock JC, Belardinelli L.

Am J Physiol Heart Circ Physiol. 2009 Sep;297(3):H1048-57. doi: 10.1152/ajpheart.00467.2009. Epub 2009 Jul 10.

17.

Modulation of the late sodium current by ATX-II and ranolazine affects the reverse use-dependence and proarrhythmic liability of IKr blockade.

Jia S, Lian J, Guo D, Xue X, Patel C, Yang L, Yuan Z, Ma A, Yan GX.

Br J Pharmacol. 2011 Sep;164(2):308-16. doi: 10.1111/j.1476-5381.2010.01181.x.

18.
19.

Cellular basis for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome.

Shimizu W, Antzelevitch C.

J Electrocardiol. 1999;32 Suppl:177-84. Review.

PMID:
10688323
20.

Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.

Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L.

J Pharmacol Exp Ther. 2004 Aug;310(2):599-605. Epub 2004 Mar 18.

Supplemental Content

Support Center